BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16637233)

  • 1. Ameliorating effect of dimethylsulfoniopropionate on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease of mice.
    Nakajima K; Minematsu M
    J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):70-4. PubMed ID: 16637233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Minematsu M; Nakajima K
    J Nutr Sci Vitaminol (Tokyo); 2008 Aug; 54(4):335-8. PubMed ID: 18797157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profile of acupuncture treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model.
    Hong MS; Park HK; Yang JS; Park HJ; Kim ST; Kim SN; Park JY; Song JY; Park HK; Jo DJ; Park SW; HwanYun D; Ban JY; Chung JH
    Neurol Res; 2010 Feb; 32 Suppl 1():74-8. PubMed ID: 20034450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the outgrowth and elongation of neurites from pheochromocytoma cells by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and preventive effects of dimethylsulfoniopropionate in the presence of nerve growth factor.
    Nakajima K; Minematsu M; Miyamoto Y
    J Nutr Sci Vitaminol (Tokyo); 2008 Apr; 54(2):176-80. PubMed ID: 18490849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    Al-Sweidi S; Morissette M; Di Paolo T
    J Neuroendocrinol; 2012 Nov; 24(11):1375-85. PubMed ID: 22672467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease.
    Liebetanz D; Baier PC; Paulus W; Meuer K; Bähr M; Weishaupt JH
    Exp Neurol; 2007 May; 205(1):207-13. PubMed ID: 17341420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
    Zhu G; Li J; He L; Wang X; Hong X
    Br J Pharmacol; 2015 May; 172(9):2354-68. PubMed ID: 25560396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
    Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
    J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer effects of a tertiary sulfonium compound, dimethylsulfoniopropionate, in green sea algae on Ehrlich ascites carcinoma-bearing mice.
    Nakajima K; Yokoyama A; Nakajima Y
    J Nutr Sci Vitaminol (Tokyo); 2009; 55(5):434-8. PubMed ID: 19926931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
    Alam G; Edler M; Burchfield S; Richardson JR
    Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
    Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
    BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Fuller RW; Hahn RA; Snoddy HD; Wikel JH
    Biochem Pharmacol; 1984 Oct; 33(19):2957-60. PubMed ID: 6333240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism.
    Fukumitsu N; Suzuki M; Fukuda T; Kiyono Y; Kajiyama S; Saji H
    Nucl Med Biol; 2006 Jan; 33(1):37-42. PubMed ID: 16459257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
    Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
    Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
    Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.
    Oyagi A; Oida Y; Hara H; Izuta H; Shimazawa M; Matsunaga N; Adachi T; Hara H
    Brain Res; 2008 Jun; 1214():169-76. PubMed ID: 18457816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.